Conectus
ATK

Picto Conectus
2016
Health (therapeutic and diagnosis)
Health (therapeutic and diagnosis)

ATK

Towards a treatment for Huntington's disease

Project description

The research of Didier Rognan, director of the Structural Chemogenomics team at the Laboratory of Therapeutic Innovation (CNRS - University of Strasbourg) is focused on studying the involvement of the BDNF-TrkB couple in certain neurodegenerative diseases.

The role of the BDNF-TrkB couple has been highlighted, particularly in Huntington's disease.

Today there is no therapeutic solution to treat this pathology, only treatments to reduce symptoms are available.
 
The objective of the research team is to develop two chemical series.

Why does Conectus invest in this project?

Conectus' financial investment will make it possible to:
- conduct a SAR (Structure Activity Relationship) study to optimize the two sets of molecules.
- clarify the mechanism of action
- develop an in vivo proof of concept on a relevant animal model

At the origin of the project:

Didier Rognan, Director of the Structural Chemogenomics team at the Laboratory of Therapeutic Innovation (CNRS - University of Strasbourg)

Focus

Conectus is investing in this project: 450 000 €.
Duration: 18 months

Back to the project list
Do you really want to remove this technology from your list ?
close